"unterm strich nur der konkurrenz helfen"????
Welcher Konkurrenz???
nochmal für dich mein lieber , obwohl du es ja weißt aber das wirst du offiziell niemals einsehen
(1) Our test is non-invasive and the sampling is painless. Studies show greater acceptance of HIV testing without blood. And higher testing rates are the key to controlling AIDS.
(2) Our test is easier to use, and it makes a perfect over the counter home test. No technicians are required and no lancets or needles are required.
(3) Our test is safer. There is no infectious agent such as blood to deal with. So no accidental needle sticks among health care workers, no risk of needle reuse because there are no needles and no disposal issues.
On Calypte’s OMT test advantages, in software parlance, if the first generation test (we won’t use names) is a version 1.0, ours is version 2.5. We point to 2 significant improvements:
(1) | We have shelf life of 18 months, or over 2X the earlier version. |
(2) | The design of our collection system is not limited to a single collection and a single oral test. A blood test is required to verify or confirm the current generation test. While Calypte’s OMT test is also limited to a single collection, our advantage is that our collection and sampling technology is such that the fluid collected can be used for more than one oral test. |
An example best illustrates this. We were contacted by a group in South Africa looking for a better HIV testing solution. They were testing initially using an oral test in their pharmacy clinics. The accuracy of their oral test was sufficiently low that the medical group conducting the tests was using an immediate blood test to verify the first test, largely defeating the purpose of the oral test. The queues of patients waiting to be tested was said to be averaging 5 hours and in many instances patients were failing to stay for the second test. Why? Perhaps scared away by the blood test? The attending nurses were also often refusing to participate in the blood tests. The charity sponsoring the tests recently approached Calypte’s charity agent for a better solution. Calypte has responded rapidly by confirming that we can provide a WHO protocol comprising two simultaneous oral tests (a diagnostic and a confirmatory, using completely different peptides that our scientists had developed and tested in parallel some time ago) from the same sample fluid. We are now perfecting that dual oral test. We have also had a strong expression of interest from Tanzania regarding this testing protocol.
Calypte wird der Globelplayer mit Märkten wie Indien , China, Russland, Afrikanische länder und USA & Europa werden folgen muhahahahaha..